1% chlorhexidine lowered bacterial load—not sepsis
A 147-neonate Malawi trial found lower adjusted skin bacterial load with 1% chlorhexidine than standard care. Clinical benefit remains untested.
NeoVT-AMR gives 1% chlorhexidine a credible laboratory signal, not a clinical victory. In this neonatal randomized trial, it lowered an adjusted skin bacterial-load surrogate versus standard care; whether cleansing prevents sepsis, death, or other patient-important outcomes remains unknown.
THE TRIAL IN ONE LINE
This exploratory, single-center, open-label factorial trial in Malawi enrolled 147 facility-born neonates before 24 hours of age with birth weight above 1000 g. Forty-two were allocated to 1% chlorhexidine (CHG), 42 to 2% CHG, 42 to octenidine 0.1% plus phenoxyethanol 2% (OHP), and 21 to standard care without antiseptic cleansing. Infants born to women in the separate maternal trial population, elective cesarean births, and infants with poor baseline skin condition were excluded.
- 1
Eligible neonates
Facility-born, younger than 24 hours, birth weight above 1000 g, and not born to a woman enrolled in the separate maternal population.
- 2
Cleansing randomization
Whole-body cleansing excluding the face and scalp with 1% CHG, 2% CHG, OHP, or standard care without antiseptic cleansing.
- 3
Frequency randomization
The active antiseptic groups were also assigned to a single application or repeat application every 24 hours through 72 hours or discharge.
- 4
Serial swabs
Neck-fold and perirectal samples were obtained at baseline and planned at 24, 48, and 72 hours or until discharge.
Was this worth carrying into your next shift?
Your reaction stays connected to your NICU360 profile.
Comments
0Join the conversation
Sign in to reply, vote, and keep your participation with your NICU360 profile.